Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA).  The meeting will be open to the public.

*Name of Committee*: Biological Response Modifiers Advisory Committee.                

*General Function of the Committee*:  To provide advice and recommendations to the agency on FDA's regulatory issues.                

*Date and Time*:  The meeting will be held on July 13, 2001, 8:30 a.m. to 4 p.m.                

*Location*: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.                

*Contact*: Gail Dapolito or Rosanna L. Harvey (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD  20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12389.  Please call the Information Line for up-to-date information on this meeting.                

*Agenda*: The committee will meet to: (1) Discuss responses to the March 6, 2000, FDA gene therapy letter (http://www.fda.gov/​cber/​letters.htm) relating to adenovirus vector titer measurements and replication competent adenovirus levels reporting, and (2) hear updates on the NIH final action on serious adverse reporting.                

*Procedure*:  Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.  Written submissions may be made to the contact person by July 6, 2001.  Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 noon.  Time allotted for each presentation may be limited.  Those desiring to make formal oral presentations should notify the contact person before July 6, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.                 

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated:  June 12, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01-15443 Filed 6-19-01; 8:45 am]

BILLING CODE 4160-01-S